bioRxiv · 10.1101/2022.03.18.484436
High neutralizing antibody levels against SARS-CoV-2 Omicron after UB-612 booster vaccination
Abstract
The highly transmissible Omicron variant has caused high rates of breakthrough infections among vaccinated and convalescent individuals. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increases neutralizing antibody levels by 131-, 61- and 49-fold against ancestral SARS-CoV-2, Omicron BA.1 and BA.2 variants, respectively. Based on the RBD protein binding antibody responses, we estimated a [~]95% efficacy against symptomatic COVID-19 caused by the ancestral strain after a UB-612 booster. Our results support UB-612 vaccine as a potent booster against current and emerging SARS-CoV-2 variants.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Guirakhoo, F., Wang, S., Wang, C. Y., Kuo, H.-K., Peng, W.-J., Liu, H., Wang, L., Johnson, M., Hunt, A., Hu, M. M., Monath, T. P., Rumyantsev, A., Goldblatt, D.. 2022-03-21. High neutralizing antibody levels against SARS-CoV-2 Omicron after UB-612 booster vaccination. https://doi.org/10.1101/2022.03.18.484436
Cite the original work for its findings. Save a collection to share your selection of sources.